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BACKGROUND
Globally, hip fractures are among the top 10 causes of disability in adults. For dis-
placed femoral neck fractures, there remains uncertainty regarding the effect of a 
total hip arthroplasty as compared with hemiarthroplasty.
METHODS
We randomly assigned 1495 patients who were 50 years of age or older and had a 
displaced femoral neck fracture to undergo either total hip arthroplasty or hemi-
arthroplasty. All enrolled patients had been able to ambulate without the assis-
tance of another person before the fracture occurred. The trial was conducted in 
80 centers in 10 countries. The primary end point was a secondary hip procedure 
within 24 months of follow-up. Secondary end points included death, serious ad-
verse events, hip-related complications, health-related quality of life, function, and 
overall health end points.
RESULTS
The primary end point occurred in 57 of 718 patients (7.9%) who were randomly 
assigned to total hip arthroplasty and 60 of 723 patients (8.3%) who were ran-
domly assigned to hemiarthroplasty (hazard ratio, 0.95; 95% confidence interval 
[CI], 0.64 to 1.40; P = 0.79). Hip instability or dislocation occurred in 34 patients 
(4.7%) assigned to total hip arthroplasty and 17 patients (2.4%) assigned to hemi-
arthroplasty (hazard ratio, 2.00; 99% CI, 0.97 to 4.09). Function, as measured with 
the total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
total score, pain score, stiffness score, and function score, modestly favored total 
hip arthroplasty over hemiarthroplasty. Mortality was similar in the two treatment 
groups (14.3% among the patients assigned to total hip arthroplasty and 13.1% 
among those assigned to hemiarthroplasty, P = 0.48). Serious adverse events occurred 
in 300 patients (41.8%) assigned to total hip arthroplasty and in 265 patients (36.7%) 
assigned to hemiarthroplasty.
CONCLUSIONS
Among independently ambulating patients with displaced femoral neck fractures, 
the incidence of secondary procedures did not differ significantly between patients 
who were randomly assigned to undergo total hip arthroplasty and those who were 
assigned to undergo hemiarthroplasty, and total hip arthroplasty provided a clinically 
unimportant improvement over hemiarthroplasty in function and quality of life over 
24 months. (Funded by the Canadian Institutes of Health Research and others; 
ClinicalTrials.gov number, NCT00556842.)
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P
atients with a hip fracture are at 
substantial risk for death, health compli-
cations, and reduced quality of life.1-4 De-
spite the high frequency of the injury, the way in 
which displaced femoral neck fractures in elderly 
patients should be managed surgically remains 
uncertain.2 Options include hemiarthroplasty, 
which involves replacing the femoral head with 
a prosthesis, or total hip arthroplasty, which in-
volves replacement of both the femoral head and 
the acetabulum with prostheses. Advocates of total 
hip arthroplasty perceive benefits with regard to 
patient function and quality of life as compared 
with hemiarthroplasty. There are concerns, how-
ever, that total hip arthroplasty has greater asso-
ciated surgical morbidity than hemiarthroplasty 
and may increase the risk of dislocation, which 
often leads to a secondary procedure to reduce 
or revise the prosthesis.1 Meta-analyses of studies 
involving patients with a displaced hip fracture 
have suggested that total hip arthroplasty results 
in fewer reoperations and substantially better func-
tion than hemiarthroplasty.4-6
We performed the Hip Fracture Evaluation 
with Alternatives of Total Hip Arthroplasty versus 
Hemi-Arthroplasty (HEALTH) trial, an expertise-
based randomized, controlled trial involving pa-
tients with a displaced femoral neck hip fracture, 
to examine the effect that total hip arthroplasty, 
as compared with hemiarthroplasty, has on the 
risk of a secondary hip procedure.
Me thods
Trial Design
Our trial was an international, expertise-based, 
randomized, controlled trial. Details of the trial 
objectives and design have been published previ-
ously.7 The protocol is available with the full text 
of this article at NEJM.org. Additional informa-
tion about the eligibility criteria, interventions, 
follow-up, outcome definitions, and statistical 
analysis are provided in Section S2 in the Supple-
mentary Appendix, available at NEJM.org.
Trial Oversight
The trial was funded by the Canadian Institutes of 
Health Research, the National Institutes of Health, 
and others. The funding sources had no role in 
the design or conduct of the trial; the collection, 
management, analysis, or interpretation of the 
data; or the preparation, review, or approval of the 
manuscript for submission. The Methods Cen-
ter, located at McMaster University, coordinated 
the trial and was responsible for randomization, 
maintenance, validation, data analysis, and trial-
center coordination. Boston Medical Center and 
New York University assisted in the coordination 
of trial sites in the United States. The steering 
committee, chaired by the principal investigators, 
designed the trial and the prespecified statistical 
analysis plan. The members of the steering com-
mittee (listed in Section S1) vouch for the com-
pleteness and accuracy of the data and for adher-
ence of the trial to the protocol.
Patients
We enrolled patients at 80 participating sites in 
Canada, the United States, Spain, the United King-
dom, the Netherlands, Norway, Finland, Australia, 
New Zealand, and South Africa. To be eligible 
for participation, patients had to be 50 years of 
age or older, had to have a low-energy displaced 
fracture of the femoral neck that was planned to 
be treated with surgery, and had to have been able 
to ambulate without the assistance of another 
person before the hip fracture occurred.
Procedures
Patients were assigned to undergo either total 
hip arthroplasty or hemiarthroplasty. Minimiza-
tion was used within each center to ensure prog-
nostic balance between the treatment groups with 
regard to age, prefracture living setting, prefrac-
ture functional status, and American Society for 
Anesthesiologists (ASA) physical status.2,8,9
Surgeons, patients, end-point adjudicators, and 
research coordinators who assessed patient end 
points were aware of the assigned treatment 
groups. The data analyst remained unaware of the 
treatment groups throughout the trial and while 
performing analyses.
To facilitate the expertise-based trial design,10 
we set expertise thresholds for surgeons’ partici-
pation. Among the 523 participating surgeons, 
277 of 283 (97.9%) of those who performed total 
hip arthroplasty and 369 of 381 (96.9%) of those 
who performed hemiarthroplasty met thresholds 
for surgical expertise. Patients underwent assess-
ment at 1 week, 10 weeks, and 6, 9, 12, 18, and 
24 months after surgery, either in person or by 
telephone.
A Quick Take is 
available at 
NEJM.org 
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End Points
The primary end point was any unplanned sec-
ondary hip procedure within 24 months after the 
initial surgery. The procedures included closed 
and open reductions of a hip dislocation, open 
reduction of a fracture, full or partial implant 
exchange, implant removal, implant adjustment, 
soft-tissue procedure, excision of heterotopic os-
sification, insertion of an antibiotic spacer, and 
other events as determined by an independent 
central adjudication committee. Secondary end 
points included death, serious adverse events, hip-
related complications, health-related quality of life, 
function, and overall health measures. Assess-
ments of function and quality of life included the 
Western Ontario and McMaster Universities Osteo-
arthritis Index (WOMAC) total score (range, 0 to 
96, with higher scores indicating worse pain, 
stiffness, and function; the minimal clinically im-
portant difference calculated in different studies 
ranges from 9 to 22), pain score (range, 0 to 20), 
stiffness score (range, 0 to 8), and function score 
(range, 0 to 68)11-14; the European Quality of Life–5 
Dimensions (EQ-5D) utility index score and visual 
analogue scale; the 12-Item Short Form General 
Health Survey (SF-12) physical and mental com-
ponent summary scores; and Timed Up and Go 
(TUG) scores.
The central adjudication committee reviewed 
secondary procedures to confirm the type of and 
reason for the procedure, as well as to confirm key 
secondary end points (death and hip-related com-
plications). Separate independent data and safety 
monitoring boards coordinated by the National 
Institutes of Health and Canadian Institutes of 
Health Research monitored trial safety and re-
viewed all serious adverse events.
Statistical Analysis
In 2006, during the initial vanguard phase of the 
trial, which had the primary goal of assessing 
feasibility, the definitive trial was conceived as a 
noninferiority trial with an anticipated sample 
of 2500 patients. However, during the transition 
phase to the definitive trial (358 patients), we made 
the strategic decision to switch to a more feasible 
superiority design.
The planned sample size was 1434 patients 
(717 patients per treatment group), calculated 
under the assumption of a 5% risk of the pri-
mary end point in the hemiarthroplasty group at 
1 year and a 45% lower relative risk of the pri-
mary end point at 2 years in the hemiarthroplasty 
group than in the total hip arthroplasty group. 
Our sample-size calculation reflected the proposed 
approach to the primary analysis, which used the 
proportional-hazards model.15 The sample size 
was based on a two-sided test with an alpha of 
0.05 and included adjustment for surgeon-level 
effects and for the expectation that 7.6% of pa-
tients would cross over from their randomly as-
signed group.
Analyses included patients in the groups to 
which they had been randomly assigned. Data 
for a given patient were censored at 24 months 
of follow-up or at the time of the last follow-up 
for patients who were lost to follow-up. The pri-
mary analysis was conducted with a proportional-
hazards model and a competing-risk framework 
(with death as the competing risk), with the per-
centage of patients with a primary end-point event, 
analyzed in a time-to-event analysis, as the out-
come. The independent variable was the proce-
dure (total hip arthroplasty or hemiarthroplasty), 
and the age, prefracture living setting, prefracture 
functional status, and ASA status were used as 
covariates. For our competing-risk analyses, we 
reported marginal estimates and used the method 
described by Zhou et al. to account for clustering 
of data according to surgeon.16 We report the 
treatment effects as hazard ratios with 95% con-
fidence intervals. Kaplan–Meier curves were con-
structed for the primary end point.
Cox proportional-hazards modeling was used 
to estimate the relative effect of total hip arthro-
plasty as compared with hemiarthroplasty on time 
to death and serious adverse events. Proportional-
hazards modeling with a competing-risk analysis 
(with death as the competing risk) was used to 
provide a marginal estimate of the relative effect 
of total hip arthroplasty as compared with hemi-
arthroplasty on the time to hip-related complica-
tions. We used multilevel models to estimate the 
effect of total hip arthroplasty as compared with 
hemiarthroplasty on quality of life, function, and 
mobility. In our multilevel analyses, we used joint 
modeling to account for death, using the method 
described by Rizopoulos.17 We analyzed the TUG 
as a dichotomous end point. For our multilevel 
analyses of quality of life, function, and mobility, 
all available data were used, with no imputation 
performed. The models did not require that a pa-
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tient have end-point scores at all follow-up visits. 
We chose alpha levels of 0.05 and 0.01 for the 
primary and secondary end points, respectively. All 
tests were two-sided, and no adjustments were 
made for multiple testing.
Before unblinding, we prespecified four sub-
group analyses that were conducted to investigate 
possible effect modification according to age, pre-
fracture living setting, prefracture functional sta-
tus, and ASA status. The primary end point was 
the dependent variable for these analyses. Because 
these were exploratory analyses, we did not make 
any adjustment for multiple testing within our 
subgroup analyses. We also performed multiple 
sensitivity analyses.
We first interpreted the results on the basis 
of a blinded review of the results of our primary 
analysis.18 The randomization code was then bro-
ken, the correct interpretation was chosen, and the 
manuscript was written. All analyses were per-
formed with SAS, version 9.4 (SAS Institute), 
and R, version 3.6.0 (R Project for Statistical Com-
puting).
R esult s
Patients
From January 2009 through May 2017, we ran-
domly assigned 1495 patients to undergo total hip 
arthroplasty (749 patients) or hemiarthroplasty 
(746 patients). The final 24-month assessments 
were completed in May 2019. Of the 1495 patients 
who underwent randomization, 1441 were in-
cluded in the final analyses. Of the 1243 patients 
who were alive at 24 months, 1058 (85.1%) had 
24-month follow-up data available for the analysis 
of the primary end point. (Details regarding pa-
tient flow and the reasons for exclusion are pro-
vided in Fig. S1 and Tables S1 and S2.)
The majority of patients were female (70.1%), 
70 years of age or older (80.2%), and able to am-
bulate without the aid of an assistive device be-
fore their fracture (74.4%), and the injury in the 
majority of the patients was a subcapital femoral 
neck fracture (61.9%). The baseline characteris-
tics were similar in the two treatment groups 
(Table 1 and Tables S3 through S5).
Surgical Care and Adherence to  
the Assigned Intervention
A total of 54 patients (7.5%) who had originally 
been assigned to total hip arthroplasty received 
hemiarthroplasty, and 21 (2.9%) who had origi-
nally been assigned to hemiarthroplasty received 
total hip arthroplasty (P<0.001). The frequency of 
crossing over did not vary substantially according 
to country. (Details regarding the patients who 
crossed over and of surgical and postoperative 
care are provided in Tables S6 through S10.)
Primary End Point
A secondary hip procedure within 24 months of 
follow-up occurred in 57 of 718 patients (7.9%) 
who had been randomly assigned to total hip ar-
throplasty and in 60 of 723 patients (8.3%) who 
had been randomly assigned to hemiarthroplasty 
(hazard ratio, 0.95; 95% confidence interval [CI], 
0.64 to 1.40; P = 0.79) (Fig. 1 and Table 2). The 
Kaplan–Meier curves show that the assumption 
of proportional hazards for the primary end point 
was not met — that is, the hazard ratio for the 
relative effects of the two interventions changed 
substantially over time. Post hoc analyses eluci-
dated the nature of this change in effect over 
time: the risk of a secondary hip procedure up 
to 1 year was higher in the total hip arthroplasty 
group than in the hemiarthroplasty group (hazard 
ratio, 1.23; 95% CI, 0.82 to 1.86; P = 0.32); after 
1 year and up to 2 years, the risk was higher in 
the hemiarthroplasty group than in the total hip 
arthroplasty group (hazard ratio, 0.23; 95% CI, 
0.08 to 0.69; P = 0.01) (Table S11). In light of the 
finding of a non–proportional-hazards function, 
we conducted a prespecified analysis of the inter-
action between time and treatment. We found that 
the log of the hazard ratio decreased by 0.097 each 
month (95% CI, 0.031 to 0.162; P = 0.004), which 
was also inconsistent with the plot of the esti-
mated log of the hazard ratio over time (Fig. S2).
Sensitivity analyses of various assumptions re-
garding the risk of the primary end point in pa-
tients who were lost to follow-up showed no sig-
nificant difference between the treatment groups. 
All other sensitivity analyses showed results simi-
lar to those in the primary analysis. Hip disloca-
tions that were treated with open or closed reduc-
tion were the most common secondary procedure 
in the total hip arthroplasty group (33 of 57 proce-
dures), and implant revisions were the most com-
mon secondary procedure in the hemiarthroplasty 
group (36 of 60 procedures). Subgroup analyses 
did not show any effect modification. (Details 
regarding the sensitivity and subgroup analyses 
are provided in Tables S12, S13, and S15.)
The New England Journal of Medicine 
Downloaded from nejm.org on November 11, 2020. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;23 nejm.org  December 5, 2019 2203
Total Hip Arthroplasty or Hemiarthroplasty
Characteristic
Total Hip Arthroplasty 
(N = 718)
Hemiarthroplasty 
(N = 723)
Age — yr† 79.1±8.3 78.6±8.6
Age — no./total no. (%)
50 to 70 yr 136/718 (18.9) 149/722 (20.6)
71 to 80 yr 249/718 (34.7) 247/722 (34.2)
≥81 yr 333/718 (46.4) 326/722 (45.2)
Sex — no./total no. (%)
Male 208/718 (29.0) 223/722 (30.9)
Female 510/718 (71.0) 499/722 (69.1)
Race or ethnic group — no./total no. (%)‡
Native or aboriginal 2/716 (0.3) 1/721 (0.1)
South Asian 3/716 (0.4) 6/721 (0.8)
East Asian 7/716 (1.0) 7/721 (1.0)
Hispanic or Latino 7/716 (1.0) 6/721 (0.8)
White 683/716 (95.4) 684/721 (94.9)
Black 12/716 (1.7) 15/721 (2.1)
Middle Eastern 2/716 (0.3) 2/721 (0.3)
Body-mass index — no./total no. (%)§
Underweight, <18.5 35/697 (5.0) 38/705 (5.4)
Normal weight, 18.5–24.9 357/697 (51.2) 336/705 (47.7)
Overweight, 25–29.9 217/697 (31.1) 243/705 (34.5)
Obese, 30–39.9 77/697 (11.0) 83/705 (11.8)
Morbidly obese, ≥40 11/697 (1.6) 5/705 (0.7)
Prefracture living status — no./total no. (%)
Institutionalized 30/718 (4.2) 27/723 (3.7)
Not institutionalized 688/718 (95.8) 696/723 (96.3)
Prefracture functional status — no./total no. (%)
Uses assistive device for ambulation 187/718 (26.0) 182/723 (25.2)
Able to ambulate without assistive device 531/718 (74.0) 541/723 (74.8)
Previous surgery to affected hip — no./total no. (%) 2/714 (0.3) 1/722 (0.1)
Major coexisting conditions — no./total no. (%)
Osteopenia 28/715 (3.9) 30/722 (4.2)
Osteoporosis 114/715 (15.9) 110/722 (15.2)
Lung disease 127/715 (17.8) 122/722 (16.9)
Diabetes 135/715 (18.9) 145/722 (20.1)
Ulcers or stomach disease 49/715 (6.9) 67/722 (9.3)
Kidney disease 71/715 (9.9) 67/722 (9.3)
Anemia or other blood disease 48/715 (6.7) 55/722 (7.6)
Depression 70/715 (9.8) 84/722 (11.6)
Cancer 65/715 (9.1) 80/722 (11.1)
Osteoarthritis, degenerative arthritis 111/715 (15.5) 91/722 (12.6)
Back pain 64/715 (9.0) 71/722 (9.8)
Rheumatoid arthritis 13/715 (1.8) 21/722 (2.9)
Heart disease 247/715 (34.5) 249/722 (34.5)
High blood pressure 434/715 (60.7) 443/722 (61.4)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding.
†  Data were missing for one patient in the hemiarthroplasty group.
‡  Race and ethnic group were reported by the patients.
§  Body-mass index is the weight in kilograms divided by the square of the height in meters.
Table 1. Patient Demographic Characteristics.*
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Secondary End Points
Over 24 months, 198 of 1441 patients (13.7%) died. 
Mortality did not differ significantly between the 
treatment groups (14.3% in the total hip arthro-
plasty group and 13.1% in the hemiarthroplasty 
group, P = 0.48) (Table 2). Serious adverse events 
occurred in 300 of 718 patients (41.8%) in the 
total hip arthroplasty group and in 265 of 723 
patients (36.7%) in the hemiarthroplasty group 
(hazard ratio, 1.16; 99% CI, 0.90 to 1.51) (Table 3). 
Overall, hip-related complications were more fre-
quent with total hip arthroplasty (Table 2). Hip 
instability or dislocation occurred in 34 patients 
(4.7%) who were assigned to total hip arthro-
plasty and 17 patients (2.4%) who were assigned 
to hemiarthroplasty (hazard ratio, 2.00; 99% CI, 
0.97 to 4.09).
Over 24 months, the functional assessment 
tests and quality-of-life questionnaires were com-
pleted by 943 to 1141 patients (depending on the 
test) at one or more follow-up visits (Table 4). Pa-
tients who underwent total hip arthroplasty had 
superior function as measured by the WOMAC 
total score (mean difference, −6.37; 99% CI, −9.18 
to −3.56), WOMAC pain score (mean difference, 
−0.93; 99% CI, −1.42 to −0.44), WOMAC stiffness 
score (mean difference, −0.44; 99% CI, −0.65 to 
−0.23), and WOMAC function score (mean differ-
ence, −4.97; 99% CI, −7.11 to −2.83). These differ-
ences between the treatment groups fell below 
the threshold for a minimal clinically important 
difference for WOMAC (range, 9 to 22 points). 
EQ-5D visual analogue scale scores, the 12-Item 
Short Form General Health Survey (SF-12) physi-
cal and mental component summary scores, and 
TUG scores did not differ significantly between 
the treatment groups during follow-up (Table 4). 
The characteristics of the patients who did and 
those who did not have data included in analyses 
of health-related quality of life, function, or over-
all health end points are shown in Table S14.
Discussion
Among patients with displaced fractures of the 
femoral neck, we found that the type of arthro-
plasty had no significant influence on the risk of 
unplanned secondary hip procedures over 24 
months. Functional end points favored total hip 
arthroplasty over hemiarthroplasty during the 
24-month period. Patients who underwent total 
hip arthroplasty had a slightly higher incidence 
of serious adverse events.
Strengths of our trial included the concealed 
randomization, expertise-based design,10 indepen-
dent adjudication of primary end-point events, and 
safeguards against interpretation bias.18 Nearly all 
participating surgeons (97.8%) met thresholds for 
surgical expertise.
Our trial had certain limitations. Patients and 
end-point assessors were unblinded in the assess-
ments of function, which left a possibility of 
bias. The percentage loss to follow-up was 14.9% 
for the analysis of our primary end point. Base-
line characteristics of patients who were lost to 
follow-up were similar to those of patients we 
followed. Sensitivity analyses in which patients 
in the total hip arthroplasty group who were lost 
to follow-up were assumed to have had a risk of 
a primary event that was up to 4 times as high 
as the risk among those with complete follow-up 
did not alter our principal findings. Data on func-
tion during follow-up were incomplete; 82.9% of 
patients completed at least one follow-up ques-
tionnaire over 24 months, with complete data 
from follow-up questionnaires available for 46.8% 
of patients at 12 months and for 42.1% of pa-
tients at 24 months. We did not use imputation 
to handle missing data; however, our analysis 
model did not require that a patient have end-
point scores at all follow-up visits, and it performs 
well as compared with other approaches for han-
Figure 1. Kaplan–Meier Curves for the Primary End Point.
The primary end point was any unplanned secondary hip procedure within 
24 months after the initial surgery. The inset shows the same data on an 
expanded y axis.
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End Point
Total Hip 
Arthroplasty 
(N = 718)
Hemiarthroplasty 
(N = 723)
Hazard Ratio 
(95% or 99% CI)* P Value†
number (percent)
Primary end point: unplanned secondary  
procedure
57 (7.9) 60 (8.3) 0.95 (0.64–1.40)‡ 0.79
Components of primary end point§
Closed reduction of hip dislocation 29 (4.0) 12 (1.7)
Open reduction of hip dislocation 4 (0.6) 2 (0.3)
Open reduction of fracture 5 (0.7) 8 (1.1)
Soft-tissue procedure 15 (2.1) 15 (2.1)
Insertion of antibiotic spacer 3 (0.4) 3 (0.4)
Full implant exchange 7 (1.0) 18 (2.5)
Partial implant exchange 19 (2.6) 18 (2.5)
Implant adjustment: reorientation of stem 0 2 (0.3)
Implant adjustment: reorientation of  
acetabulum component
2 (0.3) 0
Implant removal with no replacement 3 (0.4) 3 (0.4)
Excision heterotopic ossification 0 0
Supplementary fixation 3 (0.4) 1 (0.1)
Other 1 (0.1) 3 (0.4)
Secondary end points
Death 103 (14.3) 95 (13.1) 1.10 (0.77–1.58) 0.48
Serious adverse event¶ 300 (41.8) 265 (36.7) 1.16 (0.90–1.51) 0.13
Any hip-related complication‖ 132 (18.4) 118 (16.3) 1.13 (0.81–1.57)
Periprosthetic fracture 38 (5.3) 35 (4.8) 1.08 (0.61–1.88)
Hip instability or dislocation** 34 (4.7) 17 (2.4) 2.00 (0.97–4.09)
Superficial surgical-site infection 9 (1.3) 6 (0.8)
Deep surgical-site infection 17 (2.4) 16 (2.2)
Another wound-healing problem 6 (0.8) 5 (0.7)
Another soft-tissue procedure 11 (1.5) 11 (1.5)
Clinically important heterotopic  
ossification††
29 (4.0) 24 (3.3) 1.19 (0.62–2.30)
Abductor failure 1 (0.1) 3 (0.4)
Implant failure: loosening or subsidence 5 (0.7) 5 (0.7)
Implant failure: breakage 1 (0.1) 0
Pain 6 (0.8) 12 (1.7)
Neurovascular injury: technical error 2 (0.3) 1 (0.1)
Other 7 (1.0) 13 (1.8)
*  The hazard ratio is for total hip arthroplasty as compared with hemiarthroplasty; the 95% confidence interval (CI) is 
given for the primary end point, and 99% confidence intervals are given for the secondary end points. Proportional-
hazards regressions were performed only for hip-related complications for which at least 50 events occurred.
†  P values are from regression models of subdistribution hazards.
‡  The proportional-hazards assumption was violated, and analyses of year 1 as compared with year 2 followed a post 
hoc analysis guided by the Kaplan–Meier curve.
§  The numbers for the individual components add up to more than the total number of patients with the primary end 
point because some patients had more than one event.
¶  The marginal estimate for the competing-risk analysis is shown in the table; the conditional estimate for serious ad-
verse events was a hazard ratio of 1.19 (99% CI, 0.94 to 1.50; P = 0.06).
‖  The numbers for specific hip-related complications add up to more than the overall total number of patients with hip-
related complications because some patients had more than one event.
**  One patient in the total hip arthroplasty group and three patients in the hemiarthroplasty group who had hip instabil-
ity or dislocation were not treated operatively for this complication.
††  Clinically important heterotopic ossification was defined as class 3 or higher according to the Brooker classification.
Table 2. Trial End Points.
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dling missing patient data.19 The follow-up period 
in our trial may have been insufficient for under-
standing longer-term end points.
Our results differ from those of published 
meta-analyses reporting that the risk of reopera-
tion associated with total hip arthroplasty is 34 
to 43% lower than with hemiarthroplasty.4-6 This 
difference may, in part, be the consequence of 
longer follow-up periods in these meta-analyses 
(ranging from 1 to 13 years) or potential differ-
ences in our eligibility criteria.4-6
Our inclusion of patients who could ambu-
late independently before the fracture occurred 
(i.e., patients who did not require the assistance 
of another person to ambulate) is consistent with 
previous trials.6 Although the use of assistive 
devices was balanced between the treatment 
groups, we did not record the type of assistive 
device or the specific ambulatory capacity of the 
patients. Data on 17,985 femoral neck fractures 
over a period of 16 years from the Australian 
Joint Registry suggest that modern hemiarthro-
plasty and total hip arthroplasty have similar in-
cidences of revision over 10 years (hazard ratio, 
1.13; 95% CI, 0.95 to 1.33; P = 0.16).20 A large mul-
ticenter trial involving 298 patients with femoral 
neck fractures in Scotland showed no significant 
difference in the incidence of secondary hip pro-
cedures at 2 years (hazard ratio, 0.81; 95% CI, 
0.24 to 2.81; P = 0.74).21 Our subgroup analyses 
did not show any effect modification according 
to patient age, the use of assistive devices for 
ambulation, ASA status, or living status at the 
time of fracture. The larger number of events in 
the hemiarthroplasty group during the second 
year is in keeping with the possibility of more 
events being associated with that procedure over 
the long term.
A meta-analysis reported significantly fewer 
complications with total hip arthroplasty than 
with hemiarthroplasty (relative risk, 0.75; 95% CI, 
0.60 to 0.94; P<0.05).4 In our trial, the incidence 
End Point
Total Hip Arthroplasty 
(N = 718)
Hemiarthroplasty 
(N = 723) P Value*
number (percent)
Any serious adverse event† 300 (41.8) 265 (36.7) 0.13
Hip fracture–related serious adverse event 59 (8.2) 57 (7.9) 0.85
Neurologic serious adverse event 28 (3.9) 26 (3.6) 0.78
Respiratory serious adverse event 42 (5.8) 37 (5.1) 0.56
Cardiac serious adverse event 51 (7.1) 49 (6.8) 0.84
Renal serious adverse event 23 (3.2) 22 (3.0) 0.88
Vascular serious adverse event 22 (3.1) 16 (2.2) 0.33
Other serious adverse event 201 (28.0) 177 (24.5) 0.14
Non–trial-related fracture‡ 50 (7.0) 37 (5.1)
Non–trial-related dislocation‡ 2 (0.3) 0
Other non–trial-related injury‡ 10 (1.4) 14 (1.9)
Cellulitis 2 (0.3) 2 (0.3)
Death 103 (14.3) 95 (13.1)
Multiorgan failure 1 (0.1) 2 (0.3)
Osteoporosis, new or worsening 0 1 (0.1)
Sepsis 9 (1.3) 8 (1.1)
Reported by site as “other” 66 (9.2) 60 (8.3)
*  All P values were calculated with Fisher’s exact test with the exception of “any serious adverse event,” for which the  
P value was calculated with the Cox model.
†  The numbers for individual serious adverse events add up to more than the total because some patients had more 
than one type of serious adverse event.
‡  The determination of whether an injury was related to the trial was made by the attending surgeon.
Table 3. Serious Adverse Events.
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of serious adverse events was slightly higher in 
the total hip arthroplasty group than in the hemi-
arthroplasty group. Serious adverse events were 
not driven by a specific type of complication; 
rather, total hip arthroplasty broadly led to more 
cardiac, renal, vascular, neurologic, and respira-
tory events than hemiarthroplasty. The incidence 
of dislocation after total hip arthroplasty in our 
trial was high (4.7%). Pooled estimates from ran-
domized, controlled trials suggest a risk of disloca-
tion after total hip arthroplasty that is more than 
2.5 times as great as that associated with hemi-
arthroplasty (9% vs. 3%; relative risk, 2.53; 95% CI, 
1.05 to 6.10).5
Although limited comparative data are avail-
able, total hip arthroplasty has consistently been 
associated with better function and quality of 
life than hemiarthroplasty in previous studies.4-6 
Our findings showed slightly but significantly 
lower WOMAC scores (indicating better function) 
in the total hip arthroplasty group, as well as 
trends that favored total hip arthroplasty in EQ-5D, 
SF-12 scores, and TUG test times. However, the 
differences in WOMAC scores were deemed clini-
cally unimportant on the basis of the thresholds 
for the minimal clinically important difference.12,13
The American Academy of Orthopaedic Sur-
geons and National Institute for Health and Care 
Excellence guidelines recommend total hip ar-
throplasty in all patients with displaced femoral 
neck fractures who are able to ambulate inde-
pendently.22,23 Our findings suggest that the ad-
vantages of total hip arthroplasty may not be 
compelling. The limited advantages of total hip 
arthroplasty, as well as the possible higher risk 
of complications, may be particularly important 
in regions of the world where total hip arthro-
plasty is not easily accessible or is cost-prohibitive.
In our trial, the incidence of secondary proce-
dures after 2 years did not differ significantly 
between the total hip arthroplasty group and the 
hemiarthroplasty group. Total hip arthroplasty 
was associated with modestly better function over 
24 months but with a slightly higher incidence of 
serious adverse events than hemiarthroplasty 
among independently ambulating patients with 
displaced femoral neck fractures.
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End Point
Patients  
with Data 
(N = 1441)
Mean Difference in Score  
at 24 Mo, Total Hip Arthroplasty 
vs. Hemiarthroplasty (99% CI)*
no. (%)
WOMAC total score† 943 (65.4) −6.37 (−9.18 to −3.56)
WOMAC pain score† 990 (68.7) −0.93 (−1.42 to −0.44)
WOMAC stiffness score† 987 (68.5) −0.44 (−0.65 to −0.23)
WOMAC function score† 947 (65.7) −4.97 (−7.11 to −2.83)
EQ-5D utility index score‡ 1141 (79.2) 0.04 (−0.03 to 0.11)
EQ-5D VAS score‡ 1111 (77.1) 0.72 (−2.02 to 3.46)
SF-12 PCS§ 1006 (69.8) 1.41 (−0.33 to 3.14)
SF-12 MCS§ 1006 (69.8) 1.34 (−0.38 to 3.05)
Odds Ratio (99% CI)
TUG¶ 1268 (88.0) 0.72 (0.38 to 1.36)
*  The mean difference was obtained from the multilevel model.
†  Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
total scores range from 0 to 96, with higher scores indicating worse pain, stiff-
ness, and function; it is the sum of the pain score (range, 0 to 20), stiffness 
score (range, 0 to 8), and function score (range, 0 to 68). For the total score, 
the minimal clinically important difference calculated in different studies rang-
es from 9 to 22.
‡  The European Quality of Life–5 Dimensions (EQ-5D) measures quality of life 
in five dimensions; utility scores range from −0.109 to 1, with higher scores in-
dicating better states of health. Scores on the EQ-5D visual analogue scale 
(VAS) range from 0 to 100, with higher scores indicating better states of health.
§  The 12-Item Short Form General Health Survey (SF-12) measures health-relat-
ed quality of life and includes a physical composite score (PCS) and a mental 
composite score (MCS). Each composite score ranges from 0 to 100, with 
higher scores indicating better states of health.
¶  Timed Up and Go (TUG) results were dichotomized, with patients who took 
more than 12 seconds to complete the test or were unable to complete the 
test compared with patients who took 12 seconds or less to complete the 
test. The odds ratio (total hip arthroplasty vs. hemiarthroplasty) is for com-
pleting the test in more than 12 seconds or not being able to complete the 
test and was obtained from the multilevel model.
Table 4. Health-Related Quality of Life, Function, and Overall Health End 
Points.
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